Skip to content

Foresee Home for Monitoring Age Related Macular Degeneration (AMD)

Foresee Home for Monitoring Age Related Macular Degeneration (AMD)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01010997
Acronym
Foresee Home
Enrollment
10
Registered
2009-11-10
Start date
2009-12-31
Completion date
2012-01-31
Last updated
2012-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Keywords

AMD, CNV

Brief summary

The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD. However, the device has ability to detect the development of the lesion post treatment and therefore to asses in determination of the next treatment.

Detailed description

The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD. However, the device has ability to detect the development of the lesion post treatment and therefore to asses in determination of the next treatment. The OCT May be use as well to identify choroidal neovascularization (CNV). Comparison between the two methods will allow better understanding of both devices. The FORESEE HOME can use as an assessment tool for the progression and success of the treatment given to AMD lesions. Therefore, evaluation the size and the location of the treated lesions may serve as an additional tool.

Interventions

using the Foresee home device

Sponsors

Notal Vision Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Capable and willing to sign a consent form and participate in the study * Subjects diagnosed as CNV under treatment or Intermediate AMD in at least one eye * Did not perform more then 10 anti- VEGF injections * Age \>50 years * VA with habitual correction \>6/45 in the study eye * Computer users

Exclusion criteria

* Evidence of macular disease other than AMD or glaucoma in the study eye * Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, * Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye

Design outcomes

Primary

MeasureTime frame
To investigate the FORESEE HOME ability to diagnose AMD in different stages1 year

Secondary

MeasureTime frame
To investigate the correlation between visual fields (VF) defects map generated by the FORESEE HOME and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence Tomography(OCT).1 year

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026